AU2002211688A1 - Method for treating ischemic events affecting the central nervous system - Google Patents

Method for treating ischemic events affecting the central nervous system

Info

Publication number
AU2002211688A1
AU2002211688A1 AU2002211688A AU1168802A AU2002211688A1 AU 2002211688 A1 AU2002211688 A1 AU 2002211688A1 AU 2002211688 A AU2002211688 A AU 2002211688A AU 1168802 A AU1168802 A AU 1168802A AU 2002211688 A1 AU2002211688 A1 AU 2002211688A1
Authority
AU
Australia
Prior art keywords
nervous system
central nervous
ischemic events
treating ischemic
events affecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002211688A
Inventor
William H. Frey Ii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2002211688A1 publication Critical patent/AU2002211688A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2002211688A 2000-10-13 2001-10-12 Method for treating ischemic events affecting the central nervous system Abandoned AU2002211688A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24054900P 2000-10-13 2000-10-13
US60/240,549 2000-10-14
PCT/US2001/031956 WO2002032449A2 (en) 2000-10-13 2001-10-12 Method for treating ischemic events affecting the central nervous system

Publications (1)

Publication Number Publication Date
AU2002211688A1 true AU2002211688A1 (en) 2002-04-29

Family

ID=22906993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002211688A Abandoned AU2002211688A1 (en) 2000-10-13 2001-10-12 Method for treating ischemic events affecting the central nervous system

Country Status (4)

Country Link
US (1) US20020082215A1 (en)
EP (1) EP1370282A2 (en)
AU (1) AU2002211688A1 (en)
WO (1) WO2002032449A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776312B2 (en) * 2004-08-13 2010-08-17 Healthpartners Research Foundation Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
US9216161B2 (en) 2004-08-13 2015-12-22 Healthpartners Research Foundation Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
EP2056800B1 (en) * 2005-08-26 2015-12-09 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
US7854923B2 (en) 2006-04-18 2010-12-21 Endomedix, Inc. Biopolymer system for tissue sealing
US20070243130A1 (en) * 2006-04-18 2007-10-18 Weiliam Chen Biopolymer system for tissue sealing
US20080124395A1 (en) * 2006-06-22 2008-05-29 Weiliam Chen Formulations and devices for treatment or prevention of neural ischemic damage
MX2009001691A (en) 2006-08-31 2009-02-25 Hoffmann La Roche Method for the production of insulin-like growth factor-i.
CL2007002502A1 (en) 2006-08-31 2008-05-30 Hoffmann La Roche VARIANTS OF THE SIMILAR GROWTH FACTOR TO HUMAN INSULIN-1 (IGF-1) PEGILATED IN LISIN; METHOD OF PRODUCTION; FUSION PROTEIN THAT UNDERSTANDS IT; AND ITS USE TO TREAT ALZHEIMER'S DISEASE.
GB0704678D0 (en) * 2007-03-09 2007-04-18 Univ Bristol Pro- and anti-angiogenic treatments
US20080269109A1 (en) * 2007-04-30 2008-10-30 Becker Lance B System and method of resuscitation of a mammal
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
US20110152188A1 (en) 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
JP2014502953A (en) * 2010-08-16 2014-02-06 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク Intranasal delivery of cell permeable therapeutics
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
WO2012174481A1 (en) 2011-06-15 2012-12-20 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
US10279012B2 (en) 2013-03-11 2019-05-07 Healthpartners Research & Education Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
SG11201509419QA (en) 2013-05-15 2015-12-30 Univ Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
US10314911B2 (en) 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
CA2972975A1 (en) 2015-01-07 2016-07-14 Trigemina, Inc. Magnesium-containing oxytocin formulations and methods of use
DE102015115406A1 (en) 2015-09-11 2017-03-16 Jakob Lach Gmbh & Co. Kg Method for producing a component
DE102015107077A1 (en) 2015-05-06 2016-11-10 Jakob Lach Gmbh & Co. Kg Method of making a tool
IL262211B2 (en) 2016-04-15 2024-01-01 Univ Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
BR112020005249A2 (en) 2017-09-22 2020-09-24 The Trustees Of The University Of Pennsylvania gene therapy to treat mucopolysaccharidosis type ii
US10517988B1 (en) 2018-11-19 2019-12-31 Endomedix, Inc. Methods and compositions for achieving hemostasis and stable blood clot formation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
WO1991007947A1 (en) * 1989-12-05 1991-06-13 Ramsey Foundation Neurologic agents for nasal administration to the brain
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6407061B1 (en) * 1989-12-05 2002-06-18 Chiron Corporation Method for administering insulin-like growth factor to the brain
SE9100099D0 (en) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab USE OF GROWTH FACTOR
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
US20020169102A1 (en) * 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS

Also Published As

Publication number Publication date
US20020082215A1 (en) 2002-06-27
WO2002032449A3 (en) 2003-10-09
WO2002032449A2 (en) 2002-04-25
EP1370282A2 (en) 2003-12-17

Similar Documents

Publication Publication Date Title
AU2002211688A1 (en) Method for treating ischemic events affecting the central nervous system
AU2001238369A1 (en) Method for treating thyroid disorders
AU1786401A (en) Method for patterning devices
AU6425099A (en) Method for patterning devices
AU2001238472A1 (en) Method for treating parathyroid disorders
AU7085100A (en) Method for treating otic disorders
GB2355546B (en) Control method for engine having multiple control devices
AU2001285159A1 (en) Methods for treating endocrine disorders
AU2001259056A1 (en) Method for selectively inhibiting ghrelin action
HUP0102843A3 (en) Method for producing isoxazoline-3-yl-acyl benzene
AU2001256780A1 (en) Method for examining ischemic conditions
AU2001231104A1 (en) Methods for treating diabetes
AU2002210881A1 (en) Transdermal method
AU2001227140A1 (en) Method for inhibiting apoptosis under ischemic condition
AU2001234730A1 (en) Method for inhibiting complement activation
AU2001277938A1 (en) Method for treating angina
EP1324238A4 (en) Distributing method
AU2002214487A1 (en) Method for inducing apoptiosis
AU2001274530A1 (en) Lot distributing method
AUPP646598A0 (en) New processes for producing alpha-alanine derivative
AU2001240656A1 (en) System for producing steel
AU7957200A (en) Method for distributing pay-information
AU2001269505A1 (en) Fumarate derivative, method for producing the same
AU2001243297A1 (en) Method for treating or preventing depression
AU5214300A (en) Method for producing 2,2,4,4-tetra-substituted 1,3,5-cyclohexanetriones